Grifols, S.A.
Grifols, S.A. (GRFS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GRFS · as of Jun 8, 2026
Key Statistics
Explore Grifols, S.A. Data
grfs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 50.0%
Competitors & Peers
grfs competitorsGRFS
ATR
AVTR
BIO
CORT
DVAStock Performance
Full HistoryAbout Grifols, S.A.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supp…
what is grifols, s.a. · grfs stock overview · grifols, s.a. company profile · who is grifols, s.a. ceo · grfs NASDAQ · grifols, s.a. headquarters · grifols, s.a. business segments
About Stock Overview & Key Data
Grifols, S.A. (GRFS) is a Healthcare company in the Drug Manufacturers - General industry, listed on NASDAQ since Jun 2, 2011. As of the latest trading session, GRFS stock price is $7.64, with a market capitalization of $6.5B. The stock has returned -13.48% over the past 12 months and -18.29% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Grifols, S.A. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Grifols, S.A. reported revenue of $7.2B and net income of $386.1M. For detailed data — including Grifols, S.A. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Grifols, S.A. (GRFS) stock price is $7.64. The stock is traded on NASDAQ under the ticker symbol GRFS. The 52-week range is $7.39 – $11.14.